Effects of Melatonin on Diabetic Neuropathy and Retinopathy

Oliveira-Abreu, Klausen; Cipolla‐Neto, José; Leal‐Cardoso, J. H.

doi:10.3390/ijms23010100

Cited by 14 publications

(7 citation statements)

References 65 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has antioxidant properties, so its decrease is linked to more severe diabetic retinopathy; the decrease in melatonin leads to increased oxidative stress with more damage to capillary endothelium. We can find a relation between its levels in the blood and diabetic retinopathy stages [16].…”

Section: Discussionmentioning

confidence: 83%

Correlation Between Serum Melatonin Level and Other Indicators With Stages of Diabetic Retinopathy

Mahmoud

Hashim

Ahmed

et al. 2022

Egyptian Journal of Clinical Ophthalmology

View full text Add to dashboard Cite

Purpose: Diabetic retinopathy is considered the ghost cause of vision deterioration; it is attributed to elevated oxidative stress. Antioxidants, like melatonin, were found to be affected in diabetic retinopathy. In the present paper, we aim to explore melatonin levels in various stages of diabetic retinopathy. Method: Patients with diabetic retinopathy were recruited and divided into 3 groups (non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), and advanced diabetic eye disease). One control group was recruited (diabetics without diabetic retinopathy). Each participant was subjected to full ophthalmological examination, internal medicine evaluation, fluorescein angiography F/A, as well as optical coherence tomography (OCT) to classify the stage of diabetic retinopathy. The laboratory evaluation of melatonin, bilirubin, aspartate transferase AST, alanine transferase ALT, fasting plasma glucose FBG, hemoglobin A1c HA1c, and lipid profile were done. Data were collected and analyzed. Results: Each group includes 60 participants. We found no different sex distribution in the four groups as (P value =0.77), age in the four groups was as follows 58.35±8.56, 55.77±14.43, 59.3±10.73, 60.98± 7.60 years with (P =0.06). For diabetes-associated variables like duration, fasting glucose levels, HA1c, and medications (insulin or oral hypoglycemic), we found this result; increased duration of diabetes with raised levels of FBG, HA1C, and insulin treatment were linked with severe diabetic retinopathy affection (P value <0.0001). When assessing the plasma melatonin levels, the mean melatonin levels were decreased significantly with increased severity of diabetic retinopathy (86.04 ± 2.71, 73.05 ± 6.91, 25.82 ± 2.89, 24.28 ± 2.37 pg/ml) in the studied groups NDR, NPDR, PDR and advanced diabetic retinopathy with (P-value < 0.0001). Decreased melatonin could be a risk factor for diabetic retinopathy. As regards total bilirubin, its mean values decreased significantly with increasing severity of DR (P-value < 0.0001). Conclusion: There is a relation between the levels of serum melatonin and the severity of diabetic retinopathy.

show abstract

Section: Discussionmentioning

confidence: 83%

Correlation Between Serum Melatonin Level and Other Indicators With Stages of Diabetic Retinopathy

Mahmoud

Hashim

Ahmed

et al. 2022

Egyptian Journal of Clinical Ophthalmology

View full text Add to dashboard Cite

show abstract

“…There have only been reported relatively minor adverse effects, such as lightheadedness, headaches, nausea, and tiredness. Exogenous melatonin has not been shown in any study to have the potential to cause any major adverse effects (Andersen et al, 2016;Oliveira-Abreu et al, 2021). Table 1 summarizes the data on the effects of DN alone or in combination with melatonin on neuron cells/ tissue.…”

Section: Discussionmentioning

confidence: 99%

The neuroprotective effects of melatonin against diabetic neuropathy: A systematic review of non-clinical studies

et al. 2022

View full text Add to dashboard Cite

Backgrounds: Diabetes can cause diabetic neuropathy (DN), a nerve injury. High blood sugar (glucose) levels can harm nerves all over your body. The nerves in your legs and feet are the most commonly affected by DN. The purpose of this study was to conduct a review of melatonin’s potential neuroprotective properties against DN.Method: A full systematic search was conducted in several electronic databases (Scopus, PubMed, and Web of Science) up to March 2022 under the PRISMA guidelines. Forty-seven studies were screened using predefined inclusion and exclusion criteria. Finally, the current systematic review included nine publications that met the inclusion criteria.Result: According to in vivo findings, melatonin treatment reduces DN via inhibition of oxidative stress and inflammatory pathways. However, compared to the diabetes groups alone, melatonin treatment exhibited an anti-oxidant trend. According to other research, DN also significantly produces biochemical alterations in neuron cells/tissues. Additionally, histological alterations in neuron tissue following DN were detected.Conclusion: Nonetheless, in the majority of cases, these diabetes-induced biochemical and histological alterations were reversed when melatonin was administered. It is worth noting that the administration of melatonin ameliorates the neuropathy caused by diabetes. Melatonin exerts these neuroprotective effects via various anti-oxidant, anti-inflammatory, and other mechanisms.

show abstract

“…Currently, there are few treatments for DN, most of which include many side effects. In previous investigations, the results of melatonin [ 14 , 15 ], caffeine [ 16 ], capsaicin [ 17 ], vitamin B 12 [ 18 ], alpha-lipoic acid [ 19 ], vitamin E [ 20 ], acupuncture [ 21 ], gabapentin and duloxetine [ 22 , 23 ], pregabalin and gabapentin [ 24 ], gabapentin [ 25 , 26 ], the topical combination of clonidine and pentoxifylline [ 27 ], and clonidine gel with capsaicin cream has been studied [ 28 ]. Anticonvulsants are common medications for treating peripheral neuropathy but are not sufficiently compelling and include side effects [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial

Hassanzadeh,

Bagheri,

Majid Ahmadi

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Background Peripheral neuropathy is not only the most prevalent consequence of diabetes but also the main reason for foot ulceration, disability, and amputation. Therefore, the current study aims to determine the effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients. Methods This 12-week, randomized, and parallel-group trial was conducted to compare the efficacy of oral clonidine and gabapentin with gabapentin alone in diabetic patients in southwest Iran during the first half of 2021. Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months. The data were analyzed using SPSS-21 software. In order to report the results, descriptive indices, independent t-test, one-way analysis of covariance (ANCOVA) and analysis of variance with repeated measures were used. Results The mean and standard deviation of the age of the participants in the clonidine + gabapentin group was equal to 50.20 ± 7.44, and in the gabapentin group was equal to 50.47 ± 7.57 (t = 0.10, P-value = 0.923). This research showed a significant difference between the clonidine + gabapentin group and with gabapentin group in terms of neuropathic pain and the severity of neuropathic pain (P < 0.001). Conclusions According to this research results, clonidine + gabapentin can reduce neuropathic pain and the severity of neuropathic pain in diabetic patients. Therefore, it is recommended that healthcare professionals with diabetes expertise prescribe these medications to reduce neuropathic pain and its severity. Trial registration This study was registered in the Iranian Clinical Trials System with the ID (IRCT20211106052983N1) on 14/01/2022.

show abstract

Effects of Melatonin on Diabetic Neuropathy and Retinopathy

Cited by 14 publications

References 65 publications

Correlation Between Serum Melatonin Level and Other Indicators With Stages of Diabetic Retinopathy

Correlation Between Serum Melatonin Level and Other Indicators With Stages of Diabetic Retinopathy

The neuroprotective effects of melatonin against diabetic neuropathy: A systematic review of non-clinical studies

Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial

Contact Info

Product

Resources

About